All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Won Seog Kim, Sungkyunkwan University, Seoul, KR. We asked, What do the ELM-2 results tell us about the efficacy of odronextamab for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)?
What do the ELM-2 results tell us about the efficacy of odronextamab for R/R DLBCL?
Kim discusses results from the DLBCL cohort of the prospective phase II ELM-2 trial (NCT03888105) of odronextamab, which incorporated an optimized step-up regimen. He then highlights the promising efficacy and manageable toxicity profile of odronextamab in patients with R/R DLBCL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
FDA lifts partial clinical hold on odronextamab trials in B-cell non-Hodgkin lymphomas
On December 14, 2020, it was reported that the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on trials of odronextamab in B-cell...
Using ctDNA analysis in risk profiling of frontline DLBCL: Results from the POLARIX study
In the risk profiling of previously untreated patients with DLBCL from the POLARIX study using ctDNA, results suggested that ctDNA analysis has prognostic...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox